Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2022 | Next steps for improving outcomes for patients with oligometastatic esophagogastric cancer

Tiuri Kroese, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses the need for a randomised or prospective trial investigating the best treatments for patients with oligometastatic esophagogastric cancer, to build upon the results of the recent retropspective trial which determined that local therapy plus systemic therapy resulted in the best overall and progression-free survival for these patients. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.